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INTRODUCTION
Traumatic brain injury (TBI) affects an estimated 1.7 million people a year. Around 75% of
these cases are mild. Falls and motor vehicle accidents are among the leading causes for TBI,
with falls accounting for 60.7% of occurrences in populations 65 years or older1. As the general
population continues to expand both in age and in size, the risk of falls will increase. This poses
a problem particularly in light of the pervasive use of anticoagulants and antiplatelet agents for
this population, both of which increase the bleeding risk.
Anticoagulants and antiplatelet agents are used for a variety of conditions, including deep venous
thrombosis, atrial fibrillation, pulmonary embolism and coronary artery disease. They are also
given postoperatively for prosthetic heart valves or stent placement. An estimated 597,689 deaths
in 2010 were due to cardiovascular disease, with 80% above the age of 652. Stroke caused 129,476
deaths. The use of anticoagulants and antiplatelet agents for prevention of cardiovascular and
cerebrovascular events is irrefutable, but little literature has touched on its effects on morbidity and

mortality in those with traumatic brain injury.
This article summarizes the current literature
on the pre-TBI use of anticoagulants and antiplatelet agents and the associated morbidity
and mortality.

CASE
A 68-year-old man with a past medical
history of myocardial infarction 6 months
ago with stent placement (now on aspirin and
plavix), HTN, DM, obesity and 40 pack year
smoking complained of an intense headache
immediately prior to falling while getting up
to go to the bathroom. After the fall, his wife
called the paramedics. Shortly after arriving
in the emergency department, he became
unresponsive and was emergently intubated.
CT scan showed ICH (Figure 1). His ICH score
upon admission was 4. His coagulation profile
was normal. His platelets were decreased at
110,000/uL.

DISCUSSION
A large percentage of the population sustaining
traumatic brain injury due to falls are also those
that are likely to be on chronic antiplatelet or
anticoagulation therapy. The increased risk
of bleeding with these agents after TBI then
becomes worrisome, as increased morbidity
and mortality has been shown to occur with
any volume of bleeding, with larger volume
hemorrhages having the worst prognosis.7,8 A
small number of papers to date have looked
at warfarin, aspirin or clopidogrel use in mild
TBI patients and mortality. These studies are
summarized below and in Table 1.

Figure 1
Axial CT scans demonstrating intracerebral hemorrhage.
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Warfarin
Warfarin is a vitamin K antagonist, and works
by inhibiting the enzyme vitamin K epoxide
reductase, which is responsible for carboxylating a glutamic acid residue. This is necessary
for calcium binding, allowing connection to
phospholipids surfaces to promote clotting.
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Table 1. Summary Of Studies On The Effects Of Anticoagulation Or Antiplatelet Therapy In Patients With Traumatic Brain Injury
Study

Therapy

Number of
Subjects

Wojcik et al., 2001

Warfarin

Mina et al., 2002

Mortality

Major findings

416

7.5% wafarin
8.2% control

No difference between mortality, ICU stay, LOS,
or discharge disposition

Warfarin
Aspirin
Clopidogrel

19

47% aspirin
33% warfarin
8% control

Aspirin and warfarin significantly increased mortality

Spektor et al., 2003

Aspirin

110

Not recorded

No increased incidence of ICH in patients treated with
low-dose aspirin

Lavoie et al., 2004

Warfarin

35

40% warfarin
21% control

Higher frequency of isolate head trauma, more severe head injuries and death

Ohm et al., 2005

Aspirin
Clopidogrel

90

23% antiplatelet
8% control

Antiplatelet use in patients with ICH increased mortality

Jones et al., 2006

Clopidogrel

43

7% clopidogrel

Increased morbidity and blood transfusion requirement

Franko et al., 2006

Warfarin

159

23.9%
4.9% control

Mortality with warfarin greater than control

1,511

21.9% warfarin
15.2% control

Increased risk of mortality in patients using warfarin
before ICH compared with controls

Age a separate predictor of death

Pieracci et al., 2007

Warfarin

Wong et al., 2008

Clopidogrel

111

14% clopidogrel
3% asprin

Clopidogrel increases long-term disability and mortality

Ahmed et al., 2009

Warfarin
Aspirin
Clopidogrel
Heparin

29

20% warfarin
12.5% antiplatelet
20.6% control

No difference in mortality

Fortuna et al., 2009

Warfarin
Aspirin
Clopidogrel

166

6% clopidogrel
13% aspirin
17% warfarin
20% controls

No difference in mortality

Major et al., 2009

Aspirin
Clopidogrel

287

1.4% aspirin

Mortality rate of 21% in patients with ICH on antiplatelet therapy

Bachelani et al., 2011

Aspirin

84

Not recorded

Aspirin did not increase risk of ICH progression or poor outcome

Bonville 2011

Warfarin
Aspirin
Clopidogrel

271

12.3% aspirin
9.3% clopidogrel

Warfarin increased mortality, aspirin and clopidogrel did not

Warfarin is cleared by the cytochrome P450
system in the liver and therefore has the
potential to interact with a number of drugs.
Warfarin is indicated for prophylaxis and
treatment of venous thrombosis, pulmonary
embolism, atrial fibrillation, post valve
replacement, stroke or systemic embolization
after myocardial infarction. It is monitored
closely with PT and INR due to variable individual responses. Therapeutic levels usually
fall between 2-3 for thromboemolism or atrial
fibrillation or 2.5-3.5 with mechanical heart
valves that are in the mitral position.28
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Use of warfarin has been associated with
increased risk of intracranial hemorrhage,
more severe head trauma and increased
mortality.12 Studies have shown that higher
INR levels at admission are associated with
hemorrhage progression and subsequent
risk of mortality.29-31 The risk of mortality
in a patient anticoagulated on wafarin with
an ICH after head injury ranges in the
literature from 16-80%.13-15 Mina et al. found
a 33% (4/12) mortality rate in TBI patients
taking warfarin prior to injury versus 8%
(3/37) of controls. The severity of the injury,

irrespective of anticoagulation use also
seemed to impact mortality, with the majority
of the deaths occurring in those falling down
stairs.10 Franko et al. also found a significant
increase in mortality in patients that were
anticoagulated, 23.9% versus controls, 4.9%.19
Pieracci et al. demonstrated increased risk of
mortality in patients using warfarin before
ICH compared with patients who did not.20
Only one study looked at the development
of ICH after TBI in patients taking warfarin
and found that it was increased compared to
controls (57.1% vs. 30.5%).21 In contrast, there
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have also been studies that have not found
an increase in mortality from warfarin use.
Ahmed et al. and Fortuna et al. found no
correlation between preinjury warfarin use
and mortality.22,23 Wojcik et al. also found no
significant differences between warfarin and
the control group with respect to mortality,
ICU stay or LOS and discharge disposition.24
Aspirin
Aspirin, also known as acetylsalicylic acid, is
a non-steroidal anti-inflammatory agent with
antipyretic, anti-inflammatory, analgesic
and antiplatelet effects. It works by irreversibly binding and inhibiting cycloxygenase-1
(COX-1) and inhibiting the production of
thromboxane A2 (TXA2), which is normally
involved in platelet aggregation. The effects of
aspirin persist for the lifetime of the platelet
(8-12 days).
The USPSTF currently recommends the use
of aspirin to decrease the risk of myocardial
infarction and stroke in men and women
respectively. Aspirin use has been reported
to be as high as 61% in adults ≥65 years old.3
One of the earliest papers (1992) looking at
aspirin and hemorrhage in patients with head
injuries found that aspirin was a risk factor
in developing chronic subdural hematomas.9
More recent papers have documented the
increased risk of death with aspirin therapy
in patients with radiographic evidence of
intracranial injury.10,11 Mina et. al found a
statistically significant mortality rate (47%) in
those taking aspirin compared with controls
(8%).10 Another study by other authors at the
same institution found almost a threefold
increase of death in patients taking either
aspirin, clopidogrel or combination antiplatelet therapy compared with controls.
However, they did not match comorbid conditions between cases and controls, with 71.1%
of cases manifesting three or more conditions, compared with 34.8% in the control.11
The greater number of comorbid conditions
may have had an impact on the increased
mortality seen in the cases. In contrast, a
study by Spektor et. al found no correlation
between low-dose aspirin consumption and
the frequency or type of intracranial hemorrhage.17 Neither did Bonville et. al.21 It should
be noted that in these studies, aspirin use
was either patient-reported or gathered from
outpatient pharmacy records. There were no
bleeding times or platelet function tests done
to confirm the degree of platelet inhibition.
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Misclassification of exposure therefore may
have occurred, skewing results and potentially explaining why certain studies were
unable to see an effect of aspirin on mortality.
Clopidogrel
Clopidogrel is a thienopyridine, along with
Ticlopidine and Prasugrel. Their mechanism of action involves inhibiting the ADP
receptor, P2Y12 on platelets. ADP is stored
in platelets and released upon platelet activation and promotes further platelet activation.
Clopidogrel was first approved by FDA in
1997 after the Clopidogrel versus Aspirin in
Patients at Risk of Ischemic Events (CAPRIE)
trial in 1996 found that clopidogrel was more
effective than aspirin in reducing cardiovascular events. Clopidogrel is currently
FDA-approved for use in reducing the risk
of heart attack and stroke and PAD. It is also
used in conjunction with aspirin in patients
with stents to decrease the risk for in-stent
thrombosis.4-6
Studies looking at clopidogrel use are lacking
and to date, there is no consensus as to whether
or not preinjury clopidogrel use increases
mortality in patients with TBI. A retrospective chart review by Jones et. al did not find a
statistically significant difference in mortality
between those on clopidogrel and controls,
but did find an increased morbidity and
requirement for blood transfusions in patients
receiving preinjury clopidogrel16. These
findings agreed with those of Wong et. al,
which found that prior clopidogrel use in TBI
increased long-term disability and mortality.18
More recent studies have looked at reversing
the antiplatelet effects of aspirin and clopidogrel with platelet transfusions in post-TBI
patients.25 No clear guidelines currently exist
for antiplatelet reversal. A metanalysis by
Batchelor et al. found no clear benefit with
regards to survival in administering platelets
to those with antiplatelet-associated ICH.26
Some studies have even found those receiving
transfusions may predict worse outcomes
than those that did not receive anything.27
Recent development of assays to measure the
degree of platelet inhibition such as P2Y12
or the Aspirin Response Test may help to
establish recommendations for antiplatelet
reversal. These assays may also help accurately assess the degree of platelet inhibition
and can provide a more solid cause and effect
relationship between antiplatelet use and TBI.

CONCLUSION
Traumatic brain injury is a common cause
of death in young individuals, but the
incidence of mortality from TBI is also
increasing among the elderly. Hemorrhage
progression has been associated with poor
outcomes and patients on anticoagulation or
antiplatelet therapy coming in with TBI need
to be closely monitored for the first few days.
With a growing portion of the population on
anticoagulation and antiplatelet therapy, the
risk of hemorrhage progression will increase
and so will mortality. Studies have already
demonstrated that coagulopathies are associated with an increased risk of mortality that
is likely secondary to hemorrhage progression. A consensus however, still has yet to be
reached regarding mortality risk and patient
reported anticoagulant or antiplatelet use in
traumatic brain injury patients. The benefits
of stroke or myocardial infarction prevention have to be weighed against the risk of
hemorrhage and death in those at increased
risk for traumatic brain injury from a variety
of causes. Randomized clinical control trials
need to be carried out in order to accurately
assess the cause and effect relationship
between these agents and development of
intracranial bleeding, progression of bleeding
and mortality. RCT will also help determine
the utility of administering FFP or platelets
for reversal of coagulopathies and the effects
on morbidity.

REFERENCES
1. Traumatic Brain Injury in the United States:
Emergency Department Visits, Hopsitalizations
and Deaths 2002-2006. Center for Disease Control
and Prevention, National Center for Injury
Prevention and Control; 2004. www.cdc.gov/
TraumaticBrainInjury
2. Center for Disease Control and Prevention 2010.
Deaths: Final Data for 2010. http://www.cdc.gov/
nchs/data/dvs/deaths_2010_release.pdf
3. Ajani UA, Ford ES, Greenland KJ, Giles WH,
Mokdad AH, Aspirin use among U.S. adults:
Behavioral Risk Factor Surveillance System. AM J
Prev Med 2006;30:74-7.
4. Bertrand ME, Rupprecht H-J, Urban P, Gershlick
AH, CLASSICS Investigators. Double-blind study
of the safety of clopidogrel with and without a
loading dose in combination with aspirin compared
with ticlopidine in combination with aspirin after
coronary stenting: the Clopidogrel Aspirin Stent
International Cooperative Study (CLASSICS).
Circulation 2000; 102: 624–9.

3

Trauma

JHN Journal, Vol. 8 [2013], Iss. 1, Art. 3

5. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early
and sustained dual oral antiplatelet therapy following
percutaneous coronary intervention. A randomized
controlled trial. JAMA 2002; 288: 2411–20.
6. Mehta SR, Yusuf S, Peters RJ, et al. Effects of
pretreatment with clopidogrel and aspirin followed
by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Lancet 2001.
7. Broderick JP, Brott TG, Duldner JE, Tomsick T,
Huster G. Volume of intracerebral hemorrhage.
A powerful and easy-to-use predictor of 30-day
mortality. Stroke. 1993 Jul;24(7):987-93.
8. Perel P, Roberts I, Bouamra O, Woodford M,
Mooney J, Lecky F. Intracranial bleeding in patients
with traumatic brain injury: a prognostic study. BMC
Emerg Med. 2009 Aug 3;9:15.
9. Reymond MA, Marbet G, Radü EW, Gratzl O.
Aspirin as a risk factor for hemorrhage in patients
with head injuries. Neurosurg Rev. 1992;15(1):21-5.
10. Mina AA, Knipfer JF, Park DY, Bair HA, Howells
GA, Bendick PJ. Intracranial complications of preinjury anticoagulation in trauma patients with head
injury. J Trauma. 2002 Oct;53(4):668-72.
11. Ohm C, Mina A, Howells G, Bair H, Bendick P.
Effects of antiplatelet agents on outcomes for elderly
patients with traumatic intracranial hemorrhage.
J Trauma. 2005 Mar;58(3):518-22.
12. Lavoie A, Ratte S, Clas D, et al. Preinjury wafarin use
among elderly patients with closed head injuries in a
trauma center. J Trauma 2004;56:802-7.
13. Ferrera P, Bartfiled J. Outcomes of anticoagulated
trauma patients. Am J Emerg Med. 1999;17:154-156.
14. Mattle H, Kohler S, Huber P, Rohner M, Steinsiepe
KF. Anticoagulation-related intracranial extracerebral hemorrhage. J Neurol Neurosurg Psychiatry.
1989;52:829-837.

15. Wintzen AR, Tijssen JGP. Subdural hematoma
and oral anticoagulant therapy. Arch Neurol.
1982;39:69-72.
16. Jones K, Sharp C, Mangram AJ, Dunn EL. The
effects of preinjury clopidogrel use on older trauma
patients with head injuries. Am J Surg. 2006
Dec;192(6):743-5. PubMed PMID: 17161086.
17. Wong DK, Lurie F, Wong LL. The effects of clopidogrel on elderly traumatic brain injured patients. J
Trauma. 2008 Dec;65(6):1303-8.
18. Spektor S, Agus S, Merkin V, Constantini S.
Low-dose aspirin prophylaxis and risk of intracranial
hemorrhage in patients older than 60 years of age
with mild or moderate head injury: a prospective
study. J Neurosurg. 2003 Oct;99(4):661-5.
19. Franko J, Kish KJ, O’Connell BG, Subramanian S,
Yuschak JV. Advanced age and preinjury warfarin
anticoagulation increase the risk of mortality after
head trauma. J Trauma 2006;61:107-10
20. Peirraci FM, Eachempati SR, Shou J, Hydo LJ, Barie
PS. Use of long-term anticoagulation is associated
with traumatic intracranial hemorrhage and subsequent mortality in elderly patients hospitalized after
falls: analysis of the New York State Administrative
Database. J Trauma 2007;63:519-24.

24. Wojick R, Cipolle MD, Seislove E, Wasser TE,
Pasquale MD. Preinjury warfarin does not impact
outcome in trauma patients. J Trauma 2001;51:114751; discussion 1151-2.
25. Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J.
Emergency reversal of antiplatelet agents in patients
presenting with an intracranial hemorrhage: a clinical review. World Neurosurg. 2010 Aug-Sep;74(23):279-85.
26. Batchelor JS, Grayson A. A meta-analysis to determine the effect on survival of platelet transfusions in
patients with either spontaneous or traumatic antiplatelet medication-associated intracranial haemorrhage. BMJ Open. 2012 Apr 5;2(2):e000588.
27. Washington CW, Schuerer DJ, Grubb RL Jr. Platelet
transfusion: an unnecessary risk for mild traumatic
brain injury patients on antiplatelet therapy.
J Trauma. 2011 Aug;71(2):358-63.
28. Goldsmith I, Turpie AG, Lip GY. Valvar heart
disease and prosthetic heart valves. BMJ. 2002 Nov
23;325(7374):1228-31. Review
29. Stein SC< Young GS, Talucci, RC, Greenbaum
BH, Ross SE. Delayed brain injury after head
trauma: significance of coagulopathy. Neurosurgery
1992;30:160-165.

21. Bonville DJ, Ata A, Jahraus CB, Arnold-Lloyd T,
Salem L, Rosati C, Stain SC. Impact of preinjury
warfarin and antiplatelet agents on outcomes of
trauma patients. Surgery 2011:150:861-8.

30. Oertel M, Kelly DF, McArthur D, et al. Progressive
hemorrhage after head trama: predictors and
consequences of the evolving injury. J Neurosurg.
2002;96:109-116.

22. Ahmed N, Bialowas C, Kuo Y, Zawodniak L. Impact
of Preinjury anticoagulation in patients with traumatic brain injury. South Med J 2009;102:476-80.

31. White CL, Griffith S, Caron JL. Early Progression
of Traumatic Cerebral Contusions: characterization
and risk factors. J Trauma. 2009;67:508-515.

23. Fortuna GR, Mueller EW, James LE, Shutter LA,
Butler KL. The impact of preinjury antiplatelet
and anticoagulant pharmacotherapy on outcomes
in elderly patients with hemorrhagic brain injury.
Surgery 2008;144:598-603; discussion 603-5.

PHILADELPHIA, PA
NEUROLOGY & NEUROSURGERY

2010-2011

https://jdc.jefferson.edu/jhnj/vol8/iss1/3
DOI: https://doi.org/10.29046/JHNJ.008.1.002

JHN JOURNAL

4

13

